BEAM - Beam Therapeutics Inc

-

$undefined

N/A

(N/A)

Beam Therapeutics Inc NasdaqGS:BEAM Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease; BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. It also intends to develop BEAM-103, an anti-CD117 monoclonal antibody, and BEAM-104, a cell therapy for development in sickle cell disease and beta-thalassemia; and BEAM-201 and other potential ex vivo CAR-T therapies. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Location: 238 Main Street, Cambridge, MA, 02142, United States | Website: https://beamtx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

716.3M

Cash

1.22B

Avg Qtr Burn

-87.85M

Short % of Float

21.90%

Insider Ownership

1.22%

Institutional Own.

82.28%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
BEAM-302 Details
Alpha-1 Antitrypsin Deficiency

Phase 1/2

Data readout

BEAM-101 Details
Beta thalessemia, Sickle cell disease

Phase 1/2

Data readout

BEAM-201 Details
Blood cancer, Cancer, T-cell lymphoma, Acute lymphoblastic leukemia

Phase 1/2

Update

BEAM-301 Details
Glycogen Storage Disease Type Ia , Gene & Cell therapies

Phase 1/2

Initiation

BEAM-103 Details
Beta thalessemia, Sickle cell disease

Phase 1

Initiation